| EN

澳门PG电子游戏APP官方网站 Appoints Andrew Zhu as Senior Vice President in Charge of Sales and Marketing

Release time:2022-04-08


801aa705-2765-42af-bdac-9ea5d487a8d1.jpg

On April 11, 2022, 澳门PG电子游戏APP官方网站 Pharmaceutical Group (2096.HK) announced the appointment of Mr. Andrew Zhu as Senior Vice President. He will be responsible for the company’s innovative drug marketing management. 

 

Mr. Ren Jinsheng, Chairman and CEO of 澳门PG电子游戏APP官方网站 Pharmaceuticals, said: "We gladly welcome Mr. Andrew Zhu to 澳门PG电子游戏APP官方网站. He has more than 20 years of experience in professional marketing and sales management in multinational pharmaceutical companies. His excellent skills and leadership in innovative marketing and market expansion will further accelerate the upgrade of 澳门PG电子游戏APP官方网站’s business organization. With his help, we will build a dynamic and innovative marketing team with superb academic capability in the industry.”

 

Mr. Andrew Zhu said: "I am honored to join 澳门PG电子游戏APP官方网站 and lead the sales of innovative pharmaceuticals. The company’s patient-centric marketing concept and strong R&D pipeline give me great confidence in our future. I look forward to working with my colleagues to build 澳门PG电子游戏APP官方网站 into a leading innovative pharmaceutical company in China that provides today’s patients with medicines of the future.”

 

Mr. Andrew Zhu graduated from Zhejiang University. Before joining 澳门PG电子游戏APP官方网站, he was the Vice President of AstraZeneca China and the Head of Cardiovascular, Renal and Metabolism Business Unit. Previously, he had served in several multinational companies such as Roche, and Sanofi. Mr. Andrew Zhu has extensive expertise in business model innovation, resource integration, organization enhancement, and forward-looking market strategy.

 

About 澳门PG电子游戏APP官方网站

澳门PG电子游戏APP官方网站 Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future.” Leveraging its R&D capability and commercialization excellence, 澳门PG电子游戏APP官方网站 has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.